Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/4/2025 | $32.00 | Buy | Ladenburg Thalmann |
| 11/5/2024 | $32.00 | Buy | BofA Securities |
| 11/5/2024 | $30.00 | Buy | Canaccord Genuity |
| 11/5/2024 | $32.00 | Overweight | JP Morgan |
| 11/5/2024 | $31.00 | Buy | TD Cowen |
| 11/5/2024 | Outperform | William Blair |
SUNNYVALE, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming Bank of America Securities 2025 Health Care Conference. The presentation will take place on Wednesday, May 14, 2025, at 10:55 a.m. Pacific Standard Time / 1:55 p.m. Eastern Standard Time. Event: Bank of America Securities 2025 Health Care ConferenceDate: Wednesday, May 14, 2025Time: 10:55 a.m. PST / 1:55p.m. EST A live and archived webcast of the presentation will be availabl
Ceribell is one of only 51 companies in the U.S. to achieve FedRAMP High authorization Ceribell's breakthrough technology can now be deployed in federal healthcare facilities, including U.S. Department of Veterans Affairs hospitals, helping clinicians deliver faster diagnosis and treatment for patients at risk of non-convulsive seizures SUNNYVALE, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company transforming the diagnosis and management of patients with serious neurological conditions, announced today that its point-of-care electroencephalogram (EEG) system has received full FedRAMP® (Federal Risk and Authorization Managem
SUNNYVALE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the first quarter of 2025 after the close of trading on Thursday, May 8, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on May 8, 2025. Investors interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and providing access code 7370458. A li
—Ms. Rodenbush to lead hiring and talent development initiatives— —Mr. Price to focus on market development and penetration— SUNNYVALE, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions ("Ceribell"), today announced the appointments of Kristie Rodenbush as Chief People Officer and Brian Price as Senior Vice President of Marketing to its leadership team. "Ms. Rodenbush and Mr. Price bring an impressive wealth of experience to Ceribell, and I am confident that their leadership across our People & Culture and Marketing fu
4 - Ceribell, Inc. (0001861107) (Issuer)
4 - Ceribell, Inc. (0001861107) (Issuer)
4 - Ceribell, Inc. (0001861107) (Issuer)
DEFA14A - Ceribell, Inc. (0001861107) (Filer)
DEF 14A - Ceribell, Inc. (0001861107) (Filer)
8-K - Ceribell, Inc. (0001861107) (Filer)
4 - Ceribell, Inc. (0001861107) (Issuer)
4 - Ceribell, Inc. (0001861107) (Issuer)
SC 13G - Ceribell, Inc. (0001861107) (Subject)
SC 13D - Ceribell, Inc. (0001861107) (Subject)
SUNNYVALE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the first quarter of 2025 after the close of trading on Thursday, May 8, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on May 8, 2025. Investors interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and providing access code 7370458. A li
SUNNYVALE, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the fourth quarter and full year of 2024 after the close of trading on Tuesday, February 25, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on February 25, 2025. Investors interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and providing
SUNNYVALE, Calif., Oct. 29, 2024 /PRNewswire/ -- Ceribell, Inc. (NASDAQ:CBLL) ("Ceribell"), a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the third quarter of 2024 after the close of trading on Tuesday, November 12, 2024. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET. Investors interested in listening to the conference call may do so by dialing (80
Ladenburg Thalmann initiated coverage of CeriBell with a rating of Buy and set a new price target of $32.00
BofA Securities initiated coverage of CeriBell with a rating of Buy and set a new price target of $32.00
Canaccord Genuity initiated coverage of CeriBell with a rating of Buy and set a new price target of $30.00